Table 1.
Clinical characteristics of NNKTL from different countries.
| Reported country | Japan | Japan | China | Korea | Korea | Brazil | |
|---|---|---|---|---|---|---|---|
| Reported year | 2016 | 2010 | 2008 | 2006 | 2005 | 2011 | |
| Authors | Our institution | Suzuki et al (45) | Wu et al. (43) | Lee et al. (3) | Kim et al. (46) | Gualco et al. (47) | |
| Case number | 62 | 123 | 115 | 262 | 114 | 122 | |
| Age | Range (mean) | 20–85(53) | 14–89(52) | (47) | 9–89(45) | ||
| >60 | 22(35%) | 20(18%) | 55(21%) | 20(18%) | |||
| Sex | Male/Female | 43/19 | 81/42 | 78/29 | 170/92 | 72/42 | 85/37 |
| CLINICAL STAGE | |||||||
| I/II/III/IV | 44/13/1/4 | 55/29/8/31 | 61/26/8/12 | 83/31/0/0 | 23/2/2/4 | ||
| I+II(%) | 57(92%) | 84(68%) | 87(76%) | 200(76%) | 114(100%) | 25(81%) | |
| Symptom | Nasal obstruction | 49(70%) | 84(73%) | 97(80%) | |||
| Bloody rhinorrhea | 29(47%) | 50(44%) | |||||
| B symptom | 32(52%) | 56(46%) | 57(53%) | 92(35%) | 35(31%) | ||
| Invaded tissues | Nasal cavity | 60(97%) | 111(90%) | 115(100%) | 73(64%) | 97(80%) | |
| Hard plate | 11(18%) | 8(7%) | 15(13%) | ||||
| Facial skin | 13(21%) | 19(15%) | |||||
| Pharynx | 13(21%) | 28(23%) | 27(23%) | 21(18%) | |||
| Lymph nodes | 10(16%) | 31(25%) | 21(18%) | ||||
| Skin | 9(15%) | ||||||
| Liver | 9(15%) | 10(8%) | 4(2%) | ||||
| Lung | 10(16%) | 10(8%) | 4(2%) | ||||
| Digestive tracts | 5(8%) | 10(4%) | |||||
| Bone marrow | 3(5%) | 9(7%) | 3(3%) | 16(6%) | |||
| VAHS | 3(5%) | ||||||
| SEROLOGIC FINDINGS (HIGH CASES/TOTAL CASES) | |||||||
| High LDH | 22/61(36%) | 52(43%) | 28(26%) | 96(33%) | 34(31%) | ||
| High sIL-2R | 9/24(38%) | ||||||
| PATHOLOGIC FINDINGS (POSITIVE CASES/TOTAL CASES) | |||||||
| CD3 | 25/47(53%) | 68/86(79%) | 105/108(97%) | 104(98%) | 116/122(95%) | ||
| CD43 | 31/35(89%) | 15/17(88%) | |||||
| CD45RO | 25/35(71%) | 44/49(90%) | 103/110(94%) | 61/62(98%) | |||
| CD20 | 0/59(0%) | 1/14(7%) | 0/115(0%) | 0/106(0%) | |||
| CD56 | 61/62(98%) | 115/120(96%) | 95/105(91%) | 262(100%) | 94/106(89%) | 103/122(84%) | |
| CD16 | 5/11(45%) | 9/40(23%) | |||||
| EBER | 59/62(95%) | 93/94(99%) | 106/110(96%) | 262(100%) | 46/61(75%) | 74/74(100%) | |
| LMP1 | 25/53(47%) | 10/122(8%) | |||||
| TCR rearrangement | 12/34(35%) | 7/74(10%) | |||||